A new eBook published by MedCity News for PurpleLab highlights how RWD and SDOH can lead to more inclusive clinical trials and drugs that improve the quality of life for larger, diverse patient populations not only for NSCLC, but other conditions as well.
Using RWD to understand SDOH factors faced by patients with non-small cell lung cancer paves the way for improving health equity and more effective treatments for more people.
Small practices play a critical role in healthcare delivery, but they cannot continue to absorb ever-increasing administrative demands without consequences.
For non small cell lung cancer patients, a zip code can mean the difference between diagnosis time and treatment options.
This article is part of a series on eliminating blind spots in the patient journey by leveraging real-world data.
A one-size fits most approach to clinical trial recruitment is no longer effective. A webinar discussion emphasized the need for patient-level data to shape each phase of a drug’s lifecycle, from clinical development to market access.
The webinar, sponsored by PurpleLab and scheduled for May 22, will explore how healthcare sector companies can leverage real world data (RWD) with a focus on lung cancer.
MedCity News was at the Vive conference and spoke with executives who shared their insights for the healthcare industry.
PurpleLab and Genentech executives will explore how to leverage real world data to eliminate blind spots in the patient journey — informing every phase of a drug’s lifecycle, from clinical development to market access — in a May 22 webinar.
The webinar, scheduled for May 22, will include executives from PurpleLab and feature Genentech Principal Informatics Systems Lead Dr. Ben Freiberg. Register today!
PurpleLab® stands out from others in this sector by providing its data analytics services to several different groups of users across healthcare and pharma companies.